Prelude Therapeutics Q2 FY26 net loss narrows to $13.92 million; revenue turns to $5.7 million
Reuters2026/08/11 11:05- Prelude Therapeutics posted Q2 revenue of $5.7 million, swinging from no revenue a year earlier; net loss narrowed to $13.9 million, or $0.14 per share.
- R&D expense fell to $16.1 million from $25.8 million, on lower SMARCA2 trial costs after a 2025 pause and a workforce reduction.
- Cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million at June 30, with runway expected into Q2 2028.
- Plans to initiate a Phase 1 study of KAT6A degrader PRT13722 in HR+ breast cancer in Q4 2026, pending IND clearance; PRT12396 Phase 1 enrollment continues in PV and MF.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Will a 10-year US Treasury yield rising to 5.5% "attack" US stocks? Societe Generale warns: this could be the valuation tipping point.
Bokobza, Global Head of Asset Allocation at Société Générale, pointed out that if the 10-year U.S. Treasury yield reaches 5.5%, corporate profit growth will not be sufficient to offset the impact of rising rates on valuations, and the stock market will face substantial pressure. However, he believes that the upcoming rate hikes by the Federal Reserve and the European Central Bank will be relatively limited and will not disrupt the current economic cycle.
The Dream of Big Profits in These Altcoins Didn’t Come True: Only 229 Users Managed to Earn $10,000! Here Are the Details
XRP Stuck in Range as $1.50 Breakout Level Comes Into Focus
Cilo Cybin publishes integrated annual report for year ended March 31, 2026
Crypto prices
More
